Does the media prefer ORKA or ANAB?

In the previous week, Oruka Therapeutics had 6 more articles in the media than AnaptysBio. MarketBeat recorded 13 mentions for Oruka Therapeutics and 7 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.28 beat Oruka Therapeutics' score of 1.18 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANAB or COGT?

In the previous week, AnaptysBio had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for AnaptysBio and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.57 beat AnaptysBio's score of 1.28 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ANAB or MIRM?

In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than AnaptysBio. MarketBeat recorded 18 mentions for Mirum Pharmaceuticals and 7 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.28 beat Mirum Pharmaceuticals' score of 1.16 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TVTX or ANAB?

In the previous week, Travere Therapeutics had 2 more articles in the media than AnaptysBio. MarketBeat recorded 9 mentions for Travere Therapeutics and 7 mentions for AnaptysBio. Travere Therapeutics' average media sentiment score of 1.36 beat AnaptysBio's score of 1.28 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AnaptysBio (ANAB) Competitors

$57.46 +1.62 (+2.90%)

As of 09/3/2026 04:00 PM Eastern

Compare

ANAB vs. ORKA, COGT, MIRM, TVTX, and KNSA

Should you buy AnaptysBio stock or one of its competitors? AnaptysBio's main competitors and comparable companies include Oruka Therapeutics (ORKA), Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), and Kiniksa Pharmaceuticals International (KNSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AnaptysBio compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
AnaptysBio	-11.53%	N/A	-7.75%

In the previous week, Oruka Therapeutics had 6 more articles in the media than AnaptysBio. MarketBeat recorded 13 mentions for Oruka Therapeutics and 7 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.28 beat Oruka Therapeutics' score of 1.18 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics currently has a consensus target price of $133.00, suggesting a potential upside of 46.17%. AnaptysBio has a consensus target price of $79.85, suggesting a potential upside of 38.96%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Oruka Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

AnaptysBio has higher revenue and earnings than Oruka Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
AnaptysBio	$234.60M	7.25	-$13.23M	-$1.08	N/A

Summary

AnaptysBio beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Cogent Biosciences?

AnaptysBio (NASDAQ:ANAB) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

AnaptysBio has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Cogent Biosciences. AnaptysBio is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.25	-$13.23M	-$1.08	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

AnaptysBio currently has a consensus price target of $79.85, suggesting a potential upside of 38.96%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 47.51%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cogent Biosciences has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Cogent Biosciences	N/A	-84.47%	-47.72%

In the previous week, AnaptysBio had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for AnaptysBio and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.57 beat AnaptysBio's score of 1.28 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

AnaptysBio beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Mirum Pharmaceuticals?

AnaptysBio (NASDAQ:ANAB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

AnaptysBio has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than AnaptysBio. MarketBeat recorded 18 mentions for Mirum Pharmaceuticals and 7 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.28 beat Mirum Pharmaceuticals' score of 1.16 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has a net margin of -11.53% compared to Mirum Pharmaceuticals' net margin of -139.18%. AnaptysBio's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

AnaptysBio has higher earnings, but lower revenue than Mirum Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.25	-$13.23M	-$1.08	N/A
Mirum Pharmaceuticals	$521.31M	12.53	-$23.36M	-$14.55	N/A

AnaptysBio presently has a consensus target price of $79.85, indicating a potential upside of 38.96%. Mirum Pharmaceuticals has a consensus target price of $137.31, indicating a potential upside of 36.45%. Given AnaptysBio's higher probable upside, equities analysts clearly believe AnaptysBio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

AnaptysBio beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Travere Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

In the previous week, Travere Therapeutics had 2 more articles in the media than AnaptysBio. MarketBeat recorded 9 mentions for Travere Therapeutics and 7 mentions for AnaptysBio. Travere Therapeutics' average media sentiment score of 1.36 beat AnaptysBio's score of 1.28 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	12.78	-$25.55M	-$0.46	N/A
AnaptysBio	$234.60M	7.25	-$13.23M	-$1.08	N/A

Travere Therapeutics has a net margin of -7.35% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
AnaptysBio	-11.53%	N/A	-7.75%

Travere Therapeutics presently has a consensus price target of $61.67, indicating a potential downside of 7.32%. AnaptysBio has a consensus price target of $79.85, indicating a potential upside of 38.96%. Given AnaptysBio's higher probable upside, analysts plainly believe AnaptysBio is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Travere Therapeutics beats AnaptysBio on 9 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Kiniksa Pharmaceuticals International?

AnaptysBio (NASDAQ:ANAB) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

AnaptysBio currently has a consensus price target of $79.85, indicating a potential upside of 38.96%. Kiniksa Pharmaceuticals International has a consensus price target of $87.38, indicating a potential upside of 8.58%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Kiniksa Pharmaceuticals International has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.25	-$13.23M	-$1.08	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.27	$59.01M	$0.97	82.96

AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

In the previous week, AnaptysBio had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 7 mentions for AnaptysBio and 5 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.58 beat AnaptysBio's score of 1.28 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 31.5% of AnaptysBio shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to AnaptysBio's net margin of -11.53%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Kiniksa Pharmaceuticals International beats AnaptysBio on 12 of the 16 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANAB vs. The Competition

Export

Metric	AnaptysBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.65B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-53.20	12.66	273.29	25.38
Price / Sales	7.25	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	42.88	16.29	12.89	6.14
Net Income	-$13.23M	-$22.72M	$3.47B	$349.01M
7 Day Performance	2.10%	0.34%	0.60%	-0.27%
1 Month Performance	4.10%	8.52%	5.73%	0.68%
1 Year Performance	172.45%	52.66%	25.35%	14.84%

AnaptysBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANAB AnaptysBio	3.0493 of 5 stars	$57.46 +2.9%	$79.85 +39.0%	+155.0%	$1.65B	$234.60M	N/A	100	Positive News
ORKA Oruka Therapeutics	2.8578 of 5 stars	$99.44 -2.3%	$134.30 +35.1%	+489.3%	$6.74B	N/A	N/A	N/A	Positive News Analyst Forecast Insider Trade
COGT Cogent Biosciences	2.4787 of 5 stars	$36.72 -0.2%	$49.40 +34.5%	+167.2%	$6.39B	N/A	N/A	80	Positive News
MIRM Mirum Pharmaceuticals	3.6612 of 5 stars	$98.51 +0.4%	$137.33 +39.4%	+34.9%	$6.37B	$521.31M	N/A	140	Positive News Insider Trade
TVTX Travere Therapeutics	1.6624 of 5 stars	$67.12 +0.2%	$61.67 -8.1%	+239.3%	$6.32B	$490.73M	N/A	460	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Competitors

ANAB vs. ORKA, COGT, MIRM, TVTX, and KNSA

How does AnaptysBio compare to Oruka Therapeutics?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Summary

How does AnaptysBio compare to Travere Therapeutics?

Summary

How does AnaptysBio compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Competitors

ANAB vs. ORKA, COGT, MIRM, TVTX, and KNSA

How does AnaptysBio compare to Oruka Therapeutics?

Which has more risk and volatility, ORKA or ANAB?

Do insiders & institutionals hold more shares of ORKA or ANAB?

Is ORKA or ANAB more profitable?

Does the media prefer ORKA or ANAB?

Do analysts recommend ORKA or ANAB?

Which has stronger valuation and earnings, ORKA or ANAB?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Which has more volatility and risk, ANAB or COGT?

Which has preferable earnings and valuation, ANAB or COGT?

Do analysts prefer ANAB or COGT?

Is ANAB or COGT more profitable?

Does the media prefer ANAB or COGT?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Which has more risk and volatility, ANAB or MIRM?

Does the media refer more to ANAB or MIRM?

Is ANAB or MIRM more profitable?

Which has preferable valuation and earnings, ANAB or MIRM?

Do analysts recommend ANAB or MIRM?

Summary

How does AnaptysBio compare to Travere Therapeutics?

Which has more risk and volatility, TVTX or ANAB?

Does the media favor TVTX or ANAB?

Which has preferable valuation & earnings, TVTX or ANAB?

Is TVTX or ANAB more profitable?

Do analysts rate TVTX or ANAB?

Summary

How does AnaptysBio compare to Kiniksa Pharmaceuticals International?

Do analysts prefer ANAB or KNSA?

Which has stronger earnings & valuation, ANAB or KNSA?

Which has more risk and volatility, ANAB or KNSA?

Does the media prefer ANAB or KNSA?

Do insiders & institutionals have more ownership in ANAB or KNSA?

Is ANAB or KNSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools